153 related articles for article (PubMed ID: 20846094)
21. Lymph node histopathology in mycosis fungoides and Sézary's syndrome.
Scheffer E; Meijer CJ; Willemze R; van Vloten WA
Curr Probl Dermatol; 1990; 19():105-13. PubMed ID: 2404671
[No Abstract] [Full Text] [Related]
22. Tumor microenvironment in mycosis fungoides and Sézary syndrome.
Rubio Gonzalez B; Zain J; Rosen ST; Querfeld C
Curr Opin Oncol; 2016 Jan; 28(1):88-96. PubMed ID: 26632770
[TBL] [Abstract][Full Text] [Related]
23. Sarcoidal tissue reaction in Sézary syndrome.
Gregg PJ; Kantor GR; Telang GH; Lessin SR; Nowell PC; Vonderheid EC
J Am Acad Dermatol; 2000 Aug; 43(2 Pt 2):372-6. PubMed ID: 10901727
[TBL] [Abstract][Full Text] [Related]
24. Biopsy correlation of surface area vs. single-axis measurements on computed tomography scan of lymph nodes in patients with erythrodermic mycosis fungoides and Sézary syndrome.
Haththotuwa R; Zilinskiene L; Oliff J; Vydianath B; Amel-Kashipaz R; Stevens A; Shah F; Chaganti S; Scarisbrick J
Br J Dermatol; 2017 Sep; 177(3):877-878. PubMed ID: 28012157
[No Abstract] [Full Text] [Related]
25. Sézary syndrome without erythroderma: A review of 16 cases at Mayo Clinic.
Thompson AK; Killian JM; Weaver AL; Pittelkow MR; Davis MD
J Am Acad Dermatol; 2017 Apr; 76(4):683-688. PubMed ID: 28012574
[TBL] [Abstract][Full Text] [Related]
26. Expression pattern of the lymphatic and vascular markers VEGFR-3 and CD31 does not predict regional lymph node metastasis in cutaneous melanoma.
Wobser M; Siedel C; Schrama D; Bröcker EB; Becker JC; Vetter-Kauczok CS
Arch Dermatol Res; 2006 Feb; 297(8):352-7. PubMed ID: 16395613
[TBL] [Abstract][Full Text] [Related]
27. Expression of T-follicular helper markers in sequential biopsies of progressive mycosis fungoides and other primary cutaneous T-cell lymphomas.
Bosisio FM; Cerroni L
Am J Dermatopathol; 2015 Feb; 37(2):115-21. PubMed ID: 25406852
[TBL] [Abstract][Full Text] [Related]
28. Prognostic factors, prognostic indices and staging in mycosis fungoides and Sézary syndrome: where are we now?
Scarisbrick JJ; Kim YH; Whittaker SJ; Wood GS; Vermeer MH; Prince HM; Quaglino P
Br J Dermatol; 2014 Jun; 170(6):1226-36. PubMed ID: 24641480
[TBL] [Abstract][Full Text] [Related]
29. Staging accuracy in mycosis fungoides and sezary syndrome using integrated positron emission tomography and computed tomography.
Tsai EY; Taur A; Espinosa L; Quon A; Johnson D; Dick S; Chow S; Advani R; Warnke R; Kohler S; Hoppe RT; Kim YH
Arch Dermatol; 2006 May; 142(5):577-84. PubMed ID: 16702495
[TBL] [Abstract][Full Text] [Related]
30. [Mycosis fungoides and Sézary syndrome: diagnostic and prognostic relevance of cellular antigen expression].
Meissner K; Löning T; Rehpenning W
Hautarzt; 1991 Feb; 42(2):84-91. PubMed ID: 2037492
[TBL] [Abstract][Full Text] [Related]
31. Prognostic factors in erythrodermic mycosis fungoides and the Sézary syndrome.
Kim YH; Bishop K; Varghese A; Hoppe RT
Arch Dermatol; 1995 Sep; 131(9):1003-8. PubMed ID: 7661601
[TBL] [Abstract][Full Text] [Related]
32. [Clinicopathological differential diagnosis of mycosis fungoides/Sézary syndrome from the cutaneous type of adult T-cell leukemia/lymphoma].
Johno M; Ono T
Nihon Rinsho; 2000 Mar; 58(3):660-4. PubMed ID: 10741142
[TBL] [Abstract][Full Text] [Related]
33. Interleukin 4 and interferon-gamma expression of the dermal infiltrate in patients with erythroderma and mycosis fungoides. An immuno-histochemical study.
Sigurdsson V; Toonstra J; Bihari IC; Bruijnzeel-Koomen CA; van Vloten WA; Thepen T
J Cutan Pathol; 2000 Oct; 27(9):429-35. PubMed ID: 11028812
[TBL] [Abstract][Full Text] [Related]
34. Tumor lymphangiogenesis and melanoma metastasis.
Rinderknecht M; Detmar M
J Cell Physiol; 2008 Aug; 216(2):347-54. PubMed ID: 18481261
[TBL] [Abstract][Full Text] [Related]
35. Paucity of intraepidermal FoxP3-positive T cells in cutaneous T-cell lymphoma in contrast with spongiotic and lichenoid dermatitis.
Wada DA; Wilcox RA; Weenig RH; Gibson LE
J Cutan Pathol; 2010 May; 37(5):535-41. PubMed ID: 19674197
[TBL] [Abstract][Full Text] [Related]
36. CD164 identifies CD4
Benoit BM; Jariwala N; O'Connor G; Oetjen LK; Whelan TM; Werth A; Troxel AB; Sicard H; Zhu L; Miller C; Takeshita J; McVicar DW; Kim BS; Rook AH; Wysocka M
Arch Dermatol Res; 2017 Jan; 309(1):11-19. PubMed ID: 27766406
[TBL] [Abstract][Full Text] [Related]
37. Differential expression of cancer stem cell markers in cutaneous and systemic lymphoma.
Nicolay JP; Schneider S; Gaiser T; Felcht M; Klemke CD
Exp Dermatol; 2016 Jul; 25(7):561-3. PubMed ID: 27352825
[No Abstract] [Full Text] [Related]
38. Total body-surface area as a new prognostic variable in mycosis fungoides and Sézary syndrome.
Novelli S; García-Muret P; Mozos A; Sierra J; Briones J
Leuk Lymphoma; 2016 May; 57(5):1060-6. PubMed ID: 27096891
[TBL] [Abstract][Full Text] [Related]
39. Therapeutic and prognostic significance of PARP-1 in advanced mycosis fungoides and Sezary syndrome.
Lemchak D; Banerjee S; Digambar SS; Hood BL; Conrads TP; Jedrych J; Geskin L; Akilov OE
Exp Dermatol; 2018 Feb; 27(2):188-190. PubMed ID: 29205518
[TBL] [Abstract][Full Text] [Related]
40. Mycosis fungoides and the Sézary syndrome.
Kim YH; Hoppe RT
Semin Oncol; 1999 Jun; 26(3):276-89. PubMed ID: 10375085
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
